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It has been documented that tiotropium is less likely to induce oxygen desaturation in
stable COPD patients compared to long-acting b2-agonists (LABAs) and combined
administration of a LABA and an inhaled corticosteroid (ICS) reduces the potential for
acute effects of LABA on blood-gas tensions. In this study, we have compared the acute
effects of tiotropium 18 mg and salmeterol/fluticasone combination (SFC) 50/250 mg on
arterial blood gases in 20 patients with stable COPD. Each subject was studied on 2 days,
separated from one another by at least 4 days. Blood specimens were taken just before the
inhalation and at 15, 30, 60, 180 and 360min after inhalation of each treatment, and
spirometry was performed at the same time points. As expected, both treatments
significantly improved FEV1 (greatest changes were 0.20 L, 95% CI: 0.13–0.27 at 360min
after tiotropium; and 0.13 L, 95% CI: 0.06–0.19 at 180min after SFC). The greatest mean
changes from baseline in PaO2 were 1.7 (95% CI: 4.0 to 0.6)mmHg, p ¼ 0.134, after
tiotropium; 0.8 (95% CI: 2.2 to 0.6)mmHg, after SFC. Both changes were observed after
15min. Both drugs caused a small decrease in PaCO2 (greater changes: 1.9 (95% CI 3.2
to 0.6)mmHg, p ¼ 0.005 at 60min after tiotropium; and 2.4 (95% CI: 3.5 to 1.3)
mmHg, p ¼ 0.0002 at 180min after SFC). These results indicate that both tiotropium and
SFC are able to induce a significant long-last bronchodilation without affecting arterial
blood gases. Moreover, they confirm that the impact of tiotropium on PaO2 is small and
without clinical significance and the addition of a LABA to an ICS can reduce the potentially
dangerous acute effect of the LABA on blood gases.
& 2008 Published by Elsevier Ltd.Published by Elsevier Ltd.
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Long-acting bronchodilators, both in monotherapy or com-
bined with an inhaled corticosteroid (ICS), are cardinal in
the treatment of stable COPD.1 However, in patients with a
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better to start with combined administration of a long-
acting b2-agonist (LABA) and an ICS, as suggested by the
results of the TORCH study,2 or the long-acting bronchodi-
lator tiotropium, according the algorithm proposed by
Taskhin and Cooper.3 A recent study, which has compared
the relative efficacy of the LABA/ICS combination (salme-
terol/fluticasone propionate or SFC) 50/500 mg bd and
tiotropium 18 mg od in preventing exacerbations and related
outcomes in moderate-severe COPD, found no difference in
exacerbation rate between SFC and tiotropium.4 More
patients failed to complete the study receiving tiotropium.
A small statistically significant beneficial effect was found
on health status, with an unexpected finding of lower deaths
in SFC treated patients.
It is our opinion that, looking at the available data, the
choice between a long-acting anticholinergic drug and a
LABA/ICS combination as a first-line therapy for such a type
of patients with COPD depends on the availability of
medication and the patient’s response. There are, in any
case, other issues that that could influence this choice. For
example, when we must treat a patient with hypoxemia
caused by stable severe to very-severe COPD, the potential
difference in the impact of LABA/ICS combination and
tiotropium on blood gases could be crucial.
It has been documented that tiotropium is less likely to
induce oxygen desaturation in stable COPD patients com-
pared to LABAs,5 but also, intriguingly, that combined
administration of a LABA and an ICS reduces the potential
for acute effects of LABA on blood-gas tensions.6
Since, to our best knowledge, no study has investigated
the impact of SFC on blood gases, we have explored the
acute effects SFC on the arterial blood-gas tensions in
patients with stable COPD and compared them with those
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Figure 1 Mean changes (7S.E.) in FEV1 with time after
administration of tiotropium 18mg (squares) and salmeterol/
fluticasone combination 50/250mg (rhombi). *po0.05, **po0.01,
***po0.001 vs. baseline.Patients and methods
Twenty outpatients with moderate to severe stable COPD
and a baseline FEV1p60% predicted were enrolled. Exclu-
sion criteria included: unstable respiratory status with a
change in medication for COPD within the 4 weeks prior to
the screening visit, a known history of asthma or chronic
respiratory disease other than COPD, any clinically signifi-
cant concurrent disease, a resting PaO2p55mmHg, or use of
long-term oxygen therapy. All trial procedures were con-
ducted according to the Declaration of Helsinki at the Unit
of Respiratory Medicine, Department of Clinical and Experi-
mental Medicine and Pharmacology, University of Messina,
Italy.
This was a two-way crossover study. After a 2-week run-in
period of during which fixed-combination LABAs and ICS
were discontinued, whereas long-acting bronchodilator
were permitted, all patients received tiotropium 18 mg, or
SFC 50/250 mg from dry powder inhalers (DPIs) under
randomized, crossover conditions. Each subject was studied
for 2 days, separated from one another by at least 4 days. On
each study day, subjects were required to withhold
conventional inhaled bronchodilators for at least 12 h,
salmeterol and formoterol or long-acting theophyllines for
at least 24 h, and tiotropium for at least 48 h before study toavoid or, at least, minimize any carryover effect of drugs.
Short-acting inhaled b2-agonists were permitted soon after
each test when required. Patients were asked not to
consume cola drinks, coffee or tea and not to smoke in
the hours before and during the investigation.
The study included spirometry and blood gases. The
blood-gas analyzer output was checked daily with a standard
test sample. On each study day, after a rest of 15min while
the patient was breathing room air, an arterial catheter was
placed in the brachial artery. Samples of arterial blood
(5mL) were removed for measurement of PaO2, PaCO2, and
pH with a blood-gas analyzer. Then, each patient received
one of the two study treatments under supervision. Blood-
gas analysis was repeated at 15, 30, 60, 180, and 360min,
always on room air. Spirometric tests were performed at the
same time intervals.
The changes in PaO2 and in FEV1 after each treatment,
from the baseline obtained on that day, were the primary
outcome variables. The magnitude of changes in blood-gas
tensions and functional values at each analysis time were
compared among treatments. The paired t-test and analysis
of variance (ANOVA) were used to determine the significance
of differences among agents. Statistical significance was
accepted at po0.05.Results
As expected, both treatments significantly improved FEV1
from baseline (greatest changes were: 0.20 L, 95% CI: 0.13 to
0.27, po0.05, at 360min after tiotropium; and 0.13 L, 95%
CI: 0.06 to 0.19, po0.05, at 180min after SFC) (Figure 1).
Also FVC changed in significant manner (greatest changes
were 0.19L, 95% CI: 0.10 to 0.28, po0.05, at 180min after
tiotropium; and 0.12 L, 95% CI: 0.06 to 0.18, po0.05, at
180min after SFC. The difference between the two treat-
ments was always not significant (p40.05) (Figure 2).
The impact of both treatments on arterial blood-gas
tensions was really small. The greatest mean changes from
baseline in PaO2 were 1.7 (95% CI: 4.0 to 0.6)mmHg,
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Figure 3 Mean changes (7S.E.) in PaO2 with time after
administration of tiotropium 18 mg (squares) and salmeterol/
fluticasone combination 50/250 mg (rhombi). p was always
40.05 vs. baseline.
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Figure 4 Mean changes (7S.E.) in PaCO2 with time after
administration of tiotropium 18 mg (squares) and salmeterol/
fluticasone combination 50/250mg (rhombi). *po0.05, **po0.01,
***po0.001 vs. baseline.
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Figure 2 Mean changes (7S.E.) in FVC with time after admini-
stration of tiotropium 18 mg (squares) and salmeterol/flutica-
sone combination 50/250 mg (rhombi). *po0.05, ***po0.001 vs.
baseline.
Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation 817p ¼ 0.134, p40.05, after tiotropium; 0.8 (95% CI: 2.2 to
0.6)mmHg, p40.05, after SFC (Figure 3). Both changes
were observed after 15min. Both drugs also caused a small
decrease in PaCO2 (greater changes: 1.9 (95% CI: 3.2 to
0.6)mmHg, p ¼ 0.005 at 60min after tiotropium; and
2.4 (95% CI: 3.5 to 1.3)mmHg, p ¼ 0.0002 at 180min
after SFC) (Figure 4). The difference between the two
treatments were always not significant (p40.05) also
considering their impact on arterial blood gases.Discussion
These results indicate that both tiotropium and SFC are able
to induce a significant long-last bronchodilation without
affecting arterial blood gases. Moreover, they confirm that
the impact of tiotropium on PaO2 is small and without
clinical significance and the addition of a LABA to an ICS canreduce the potentially dangerous acute effect of the LABA
on blood gases.
In a previous study, it has been documented that
salmeterol is able to induce a significant although transient
decrease in PaO2.
5 The transient decrease in PaO2 with
b-adrenergic agents has been attributed to the pulmonary
vasodilator action of these agents7 due to the activation of
b-adrenoceptors that are present in pulmonary vessels.8
A possible explanation of the interference of fluticasone on
the acute effect of salmeterol on blood gases is linked to the
documented potential of ICSs to exert an acute reduction of
bronchial blood flow.9 This effect might be explained by the
capacity of corticosteroids to interfere with noradrenaline
uptake by smooth-muscle cells of human bronchial arteries
(extraneural uptake: uptake2). It could consequently in-
crease noradrenaline concentration at a-adrenergic recep-
tor sites of the bronchial vascular smooth muscle and
explain the corticosteroid-induced vasoconstriction.10 The
pulmonary vasculature expresses a-adrenoceptors. The
stimulation of these receptors induces produces vasocon-
striction.11 This effect might divert blood flow away from
poorly ventilated alveoli to the regions that are better
ventilated, thereby optimizing ventilation/perfusion ratio
matching, and maintaining an adequate systemic PaO2.
11
Intriguingly, it has been demonstrated in vitro that, uptake2
is inhibited by steroid hormones through a nongenomic
action.12 This nongenomic action occurs within seconds to a
few minutes.13 Therefore, it could justify why the protec-
tive action of fluticasone on the vascular effect of
salmeterol is immediate, as documented by our datas.
These results suggest that the impact of LABA/ICS
combination and tiotropium on blood gases is not crucial
in the choice between a long-acting anticholinergic drug and
a LABA/ICS combination for treating a patient with
hypoxemia caused by stable severe to very-severe COPD.
They also confirm our opinion that tiotropium might be
preferable in all patients with hypoxemia caused by stable
COPD that do not need ICSs because it does not seem to
carry a risk of worsening systemic hypoxemia.
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